- Published on
Diagnostic Tests – Estrogen and Progesterone Receptors (ER/PR)
1. What Are These Tests?
Estrogen and progesterone receptor (ER/PR) testing is performed on all newly diagnosed breast cancer specimens to determine whether the tumor expresses hormone receptors. These receptors, when present on cancer cells, indicate that the tumor’s growth is influenced by estrogen or progesterone signaling. Identifying ER/PR positivity is crucial because it predicts whether the cancer is likely to respond to hormone-blocking therapy. In practice, a tissue sample from the breast tumor is analyzed using immunohistochemistry (IHC) to detect receptor presence. A tumor may be positive for estrogen receptors alone, progesterone receptors alone, or both.
2. What Is the Therapy?
Patients whose tumors express either estrogen receptors, progesterone receptors, or both are candidates for hormone (endocrine) therapy. The standard treatments include medications such as tamoxifen or raloxifene, which block estrogen’s action on breast tissue. Tamoxifen is most commonly used and is particularly effective when both estrogen and progesterone receptors are positive, as dual positivity predicts a stronger therapeutic response. These agents help reduce recurrence risk, shrink residual disease, and improve long-term outcomes by preventing estrogen-driven tumor growth. In some cases—especially in postmenopausal women—aromatase inhibitors (e.g., anastrozole, letrozole, exemestane) may also be used, although the classic board-style answer based on your content focuses on tamoxifen or raloxifene.
1. What Are These Tests?
Estrogen and progesterone receptor (ER/PR) testing is performed on all newly diagnosed breast cancer specimens to determine whether the tumor expresses hormone receptors. These receptors, when present on cancer cells, indicate that the tumor’s growth is influenced by estrogen or progesterone signaling. Identifying ER/PR positivity is crucial because it predicts whether the cancer is likely to respond to hormone-blocking therapy. In practice, a tissue sample from the breast tumor is analyzed using immunohistochemistry (IHC) to detect receptor presence. A tumor may be positive for estrogen receptors alone, progesterone receptors alone, or both.
2. What Is the Therapy?
Patients whose tumors express either estrogen receptors, progesterone receptors, or both are candidates for hormone (endocrine) therapy. The standard treatments include medications such as tamoxifen or raloxifene, which block estrogen’s action on breast tissue. Tamoxifen is most commonly used and is particularly effective when both estrogen and progesterone receptors are positive, as dual positivity predicts a stronger therapeutic response. These agents help reduce recurrence risk, shrink residual disease, and improve long-term outcomes by preventing estrogen-driven tumor growth. In some cases—especially in postmenopausal women—aromatase inhibitors (e.g., anastrozole, letrozole, exemestane) may also be used, although the classic board-style answer based on your content focuses on tamoxifen or raloxifene.
0 Comments
